Journal profile · Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
Pharmacology Research & Perspectives
ISSN 2052-1707 · Wiley-Blackwell · ENGLAND
Pharmacology Research & Perspectives: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.62; fully open access; APC about USD 4,280; median 121 days to acceptance (90 articles, last 24 months); acceptance rate 29% (journal website); 167 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Pharmacology Research & Perspectives is published by Wiley-Blackwell and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Receptor Mechanisms and Signaling, Pharmacogenetics and Drug Metabolism and Drug Transport and Resistance Mechanisms, together about 24.3% of its articles. Its main subfields are Pharmacology. (generated from OpenAlex topic counts and CAS ranking data)
Pharmacology Research & Perspectives is an open access journal publishing research and reviews in all areas of fundamental, applied and clinical pharmacology.
From the journal's Aims & Scope
Research area (LetPub): Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
Editor-in-chief Jennifer MartinPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Receptor Mechanisms and SignalingBiochemistry, Genetics and Molecular Biology9.4%
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics8.2%
- Drug Transport and Resistance MechanismsMedicine6.7%
- Neuroscience and Neuropharmacology ResearchNeuroscience5%
- Antibiotics Pharmacokinetics and EfficacyMedicine4.7%
- Neuropeptides and Animal PhysiologyNeuroscience4.6%
- Cholinesterase and Neurodegenerative DiseasesMedicine4.4%
- Pharmacological Effects and Toxicity StudiesMedicine4.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.62LetPub ·
- Impact factor (publisher) 2025
- 2.6Publisher website ·
- CiteScore 2026-06
- 4.5LetPub ·
- CiteScore (publisher) 2025
- 4.5Publisher website ·
- SJR 2026-06
- 0.74LetPub ·
- SNIP 2026-06
- 0.85LetPub ·
- h-index
- 62OpenAlex ·
- i10-index
- 720OpenAlex ·
- 2-year mean citedness
- 3.57OpenAlex ·
- Self-citation rate
- 3.8%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 145LetPub ·
- Articles per year (publisher) 2025
- 154Publisher website ·
- Downloads per year (publisher) 2025
- 713,807Publisher website ·
Articles by year OpenAlex count · 1,637 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 115 | 115 | 30 |
| 2025 | 167 | 167 | 562 |
| 2024 | 151 | 151 | 952 |
| 2023 | 116 | 116 | 851 |
| 2022 | 144 | 144 | 1,642 |
| 2021 | 211 | 211 | 3,886 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
121 daysMedian, submission to acceptance · P25–P75 90 days – 184 days
- Acceptance to online
- median 20 days (90 articles)
- Submission to online
- median 150 days
- Sample
- 90 articles with submission and acceptance dates (318 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 20 weeksLetPub ·
- Acceptance rate (publisher) 2025
- 29%Publisher website ·
- Submission to first decision 2025
- 23 daysPublisher website ·
- Submission to acceptance 2025
- 134 daysPublisher website ·
- Acceptance to publication 2025
- 19 daysPublisher website ·
- Submission to publication (journal-reported)
- about 20 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 3,130 / GBP 2,700 / USD 4,280 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 4,160 / EUR 3,040 / GBP 2,620 | — | — | |
| LetPub | USD 3,850 / GBP 2,420 / EUR 2,810 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Wiley-Blackwell
- Country or region
- ENGLAND
- Language
- English
- ISSN
- 2052-1707
- Official links
- Journal homepage ↗DOAJ
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Pharmacology Research & Perspectives
What CAS zone is Pharmacology Research & Perspectives in?
In the 2025 upgraded edition of the CAS Journal Ranking, Pharmacology Research & Perspectives is in Zone 4 of Medicine, and in Zone 3 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Pharmacology Research & Perspectives?
The latest impact factor listed by LetPub is 2.62; CiteScore 4.5, h-index 62.
How long does peer review take at Pharmacology Research & Perspectives?
Based on the dates recorded on 90 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 121 days (interquartile range 90–184 days); authors report an average review time of about 20 weeks; the journal's website gives an acceptance rate of 29% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Pharmacology Research & Perspectives?
According to LetPub and DOAJ records, Pharmacology Research & Perspectives is indexed in SCIE, Scopus and DOAJ.
Is Pharmacology Research & Perspectives open access, and what is the APC?
Pharmacology Research & Perspectives is a fully open-access journal. APC about USD 4,280.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .